3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
6
Sarcoma
4
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Neurilemmoma
1
Nerve Sheath Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Meningioma
1
Male Urogenital Diseases
1
Lung Neoplasms
1
Locally Recurrent Rectal Cancer
1
Head and Neck Neoplasms
1
Female Urogenital Diseases
1
Interventions
pembrolizumab
21
enfortumab vedotin
13
Gemcitabine
12
Nivolumab
8
Cisplatin
8
Carboplatin
8
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Docetaxel
5
toripalimab
4
sacituzumab govitecan
4
Paclitaxel
4
Ipilimumab
4
atezolizumab
3
Mitomycin
3
Fluorouracil
3
disitamab vedotin
2
cabozantinib
2
avelumab
2
Radiosurgery
2
Platinum
2
Injections
2
Immunotherapy
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Biopsy
2
zanidatamab
1
tremelimumab
1
tamibarotene
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Transitional Cell
×
Radiation Dose Hypofractionation
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled